Non-equivalence of key positively charged residues of the free fatty acid 2 receptor in the recognition and function of agonist versus antagonist ligands

Journal of Biological Chemistry

Volumn 291, Issue 1, 2016, Pages 303-317

  Sergeev, Eugenia ^a   Hansen, Anders Højgaard ^b   Pandey, Sunil K ^b   MacKenzie, Amanda E ^a   Hudson, Brian D ^a   Ulven, Trond ^b   Milligan, Graeme ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION ANALYSIS; AMINO ACIDS; ARGININE; BINS; CARBOXYLATION; DISEASES; FUNCTIONS; LIGANDS;

BACTERIAL FERMENTATIONS; INFLAMMATORY DISEASE; MOLECULAR DETERMINANTS; MOLECULAR MODELING STUDIES; NEGATIVELY CHARGED; SHORT CHAIN FATTY ACIDS (SCFAS); THERAPEUTIC TARGETS; TRANS-MEMBRANE DOMAINS;

FATTY ACIDS;

ARGININE; CARBOXYLIC ACID; FREE FATTY ACID 2; FREE FATTY ACID 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG; 4-(((R)-1-(BENZO(B)THIOPHENE-3-CARBONYL)-2-METHYL-AZETIDINE-2-CARBONYL)-(3-CHLORO-BENZYL)-AMINO)-BUTYRIC ACID; AMINO ACID; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; CELL SURFACE RECEPTOR; ESTER; G-PROTEIN COUPLED RECEPTOR 43, HUMAN; LIGAND; MUTANT PROTEIN; THIOPHENE DERIVATIVE; TRITIUM;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; ISOTOPE LABELING; LIGAND BINDING; MOLECULAR MODEL; MUTAGENESIS; PRIORITY JOURNAL; AGONISTS; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; CHEMISTRY; HEK293 CELL LINE; HUMAN; KINETICS; METABOLISM;

AMINO ACIDS; BINDING SITES; BINDING, COMPETITIVE; BUTYRATES; BUTYRIC ACID; ESTERS; HEK293 CELLS; HUMANS; KINETICS; LIGANDS; MODELS, MOLECULAR; MUTANT PROTEINS; RECEPTORS, CELL SURFACE; THIOPHENES; TRITIUM;

EID: 84952941040     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.687939     Document Type: Article

References (53)

1. Tan, J., McKenzie, C., Potamitis, M., Thorburn, A. N., Mackay, C. R., and Macia, L. (2014) The role of short-chain fatty acids in health and disease. Adv. Immunol. 121, 91-119
2. Natarajan, N., and Pluznick, J. L. (2014) From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology. Am. J. Physiol. Cell Physiol. 307, C979-C985
3. Trompette, A., Gollwitzer, E. S., Yadava, K., Sichelstiel, A. K., Sprenger, N., Ngom-Bru, C., Blanchard, C., Junt, T., Nicod, L. P., Harris, N. L., and Marsland, B. J. (2014) Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 20, 159-166
4. Stoddart, L. A., Smith, N. J., and Milligan, G. (2008) International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol. Rev. 60, 405-417
5. Milligan, G., Stoddart, L. A., and Smith, N. J. (2009) Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. Br. J. Pharmacol. 158, 146-153
6. Layden, B. T., Angueira, A. R., Brodsky, M., Durai, V., and Lowe, W. L., Jr. (2013) Short chain fatty acids and their receptors: new metabolic targets. Transl. Res. 161, 131-140
7. Milligan, G., Ulven, T., Murdoch, H., and Hudson, B. D. (2014) G-proteincoupled receptors for free fatty acids: nutritional and therapeutic targets. Br. J. Nutr. 111, S3-S7
8. Ballesteros, J. A., and Weinstein, H. (1995) Integrated methods for modeling G-protein coupled receptors. Methods Neurosci. 25, 366-428
9. Stoddart, L. A., Smith, N. J., Jenkins, L., Brown, A. J., and Milligan, G. (2008) Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids. J. Biol. Chem. 283, 32913-32924
10. Hudson, B. D., Due-Hansen, M. E., Christiansen, E., Hansen, A. M., Mackenzie, A. E., Murdoch, H., Pandey, S. K., Ward, R. J., Marquez, R., Tikhonova, I. G., Ulven, T., and Milligan, G. (2013) Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J. Biol. Chem. 288, 17296-17312
11. Schmidt, J., Smith, N. J., Christiansen, E., Tikhonova, I. G., Grundmann, M., Hudson, B. D., Ward, R. J., Drewke, C., Milligan, G., Kostenis, E., and Ulven, T. (2011) Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J. Biol. Chem. 286, 10628-10640
12. Tolhurst, G., Heffron, H., Lam, Y. S., Parker, H. E., Habib, A. M., Diakogiannaki, E., Cameron, J., Grosse, J., Reimann, F., and Gribble, F. M. (2012) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61, 364-371
13. Hudson, B. D., Tikhonova, I. G., Pandey, S. K., Ulven, T., and Milligan, G. (2012) Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. J. Biol. Chem. 287, 41195-41209
14. Ulven, T. (2012) Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front. Endocrinol. 3, 111
15. Hudson, B. D., Ulven, T., and Milligan, G. (2013) The therapeutic potential of allosteric ligands for free fatty acid-sensitive GPCRs. Curr. Top. Med. Chem. 13, 14-25
16. Smith, N. J., Ward, R. J., Stoddart, L. A., Hudson, B. D., Kostenis, E., Ulven, T., Morris J. C., Tränkle, C., Tikhonova, I. G., Adams, D. R., and Milligan, G. (2011) Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol. Pharmacol. 80, 163-173
17. Lee, T., Schwandner, R., Swaminath, G., Weiszmann, J., Cardozo, M., Greenberg, J., Jaeckel, P., Ge, H., Wang, Y., Jiao, X., Liu, J., Kayser, F., Tian, H., and Li, Y. (2008) Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Mol. Pharmacol. 74, 1599-1609
18. Wang, Y., Jiao, X., Kayser, F., Liu, J., Wang, Z., Wanska, M., Greenberg, J., Weiszmann, J., Ge, H., Tian, H., Wong, S., Schwandner, R., Lee, T., and Li, Y. (2010) The first synthetic agonists of FFA2: discovery and SAR of phenylacetamides as allosteric modulators. Bioorg. Med. Chem. Lett. 20, 493-498
19. Pizzonero, M., Dupont, S., Babel, M., Beaumont, S., Bienvenu, N., Blanqué, R., Cherel, L., Christophe, T., Crescenzi, B., De Lemos, E., Delerive, P., Deprez, P., De Vos, S., Djata, F., Fletcher, S., et al. (2014) Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. J. Med. Chem. 57, 10044-10057
20. Hansen, S. V., and Ulven, T. (2015) Oxalyl chloride as a practical carbon monoxide source for carbonylation reactions. Org. Lett. 17, 2832-2835
21. Ward, R. J., Alvarez-Curto, E., and Milligan, G. (2011) Using the Flp-InTM T-RexTM system to regulate GPCR expression. Methods Mol. Biol. 746, 21-37
22. Hudson, B. D., Shimpukade, B., Milligan, G., and Ulven, T. (2014) The molecular basis of ligand interaction at free fatty acid receptor 4 (FFA4/ GPR120). J. Biol. Chem. 289, 20345-20358
23. MacKenzie, A. E., Caltabiano, G., Kent, T. C., Jenkins, L., McCallum, J. E., Hudson, B. D., Nicklin, S. A., Fawcett, L., Markwick, R., Charlton, S. J., and Milligan, G. (2014) The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. Mol. Pharmacol. 85, 91-104
24. Ward, R. J., Pediani, J. D., and Milligan, G. (2011) Heteromultimerization of cannabinoid CB(1) receptor and orexin OX(1) receptor generates a unique complex in which both protomers are regulated by orexin A. J. Biol. Chem. 286, 37414-37428
25. Alvarez-Curto, E., Ward, R. J., Pediani, J. D., and Milligan, G. (2010) Ligand regulation of the quaternary organization of cell surface M3 muscarinic acetylcholine receptors analyzed by fluorescence resonance energy transfer (FRET) imaging and homogeneous time-resolved FRET. J. Biol. Chem. 285, 23318-23330
26. Milligan, G. (2003) Principles: extending the utility of [35S]GTPγS binding assays. Trends Pharmacol. Sci. 24, 87-90
27. Cooper, T., McMurchie, E. J., and Leifert, W. R. (2009) [35S]GTPγS binding in G protein-coupled receptor assays. Methods Mol. Biol. 552, 143-151
28. Hulme, E. C., and Birdsall, N. J. (1992) in Receptor-Ligand Interactions: A Practical Approach (Hulme, E. C., ed) pp. 63-176, IRL Press at Oxford University Press, Oxford, UK
29. Dowling, M. R., and Charlton, S. J. (2006) Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinicM3receptor. Br. J. Pharmacol. 148, 927-937
30. Sykes, D. A., and Charlton, S. J. (2012) Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonists. Br. J. Pharmacol. 165, 2672-2683
31. Srivastava, A., Yano, J., Hirozane, Y., Kefala, G., Gruswitz, F., Snell, G., Lane, W., Ivetac, A., Aertgeerts, K., Nguyen, J., Jennings, A., and Okada, K. (2014) High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513, 124-127
32. Gouy, M., Guindon, S., and Gascuel, O. (2010) SeaView version 4: a multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol. Biol. Evol. 27, 221-224
33. Olsson, M. H., Søndergaard, C. R., Rostkowski, M., and Jensen, J. H. (2011) PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J. Chem. Theor. Comput. 7, 525-537
34. Schrödinger Suite 2013-2 Protein Preparation Wizard 2013-2 (2013) Epik version 2.4, Schrödinger, LLC, New York
35. Banks, J. L., Beard, H. S., Cao, Y., Cho, A. E., Damm, W., Farid, R., Felts, A. K., Halgren, T. A., Mainz, D. T., Maple, J. R., Murphy, R., Philipp, D. M., Repasky, M. P., Zhang, L. Y., Berne, B. J., et al. (2005) Integrated modeling program, applied chemical theory (IMPACT). J. Comput. Chem. 26, 1752-1780
36. Garland, S. L., and Gloriam, D. E. (2011) A ligand's view of target similarity: chemogenomic binding site-directed techniques for drug discovery. Curr. Top. Med. Chem. 11, 1872-1881
37. Shonberg, J., Kling, R. C., Gmeiner, P., and Löber, S. (2015) GPCR crystal structures: medicinal chemistry in the pocket. Bioorg. Med. Chem. 23, 3880-3906
38. Kooistra, A. J., Leurs, R., de Esch, I. J., and de Graaf, C. (2014) From three-dimensional GPCR structure to rational ligand discovery. Adv. Exp. Med. Biol. 796, 129-157
39. Hulme, E. C. (2013) GPCR activation: a mutagenic spotlight on crystal structures. Trends Pharmacol. Sci. 34, 67-84
40. Jaakola, V. P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y., Lane, J. R., Ijzerman, A. P., and Stevens, R. C. (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322, 1211-1217
41. Blad, C. C., Tang, C., and Offermanns, S. (2012) G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat. Rev. Drug Discov. 11, 603-619
42. Hara, T., Hirasawa, A., Ichimura, A., Kimura, I., and Tsujimoto, G. (2011) Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders. J. Pharm. Sci. 100, 3594-3601
43. Hudson, B. D., Smith, N. J., and Milligan, G. (2011) Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors. Adv. Pharmacol. 62, 175-218
44. Watterson, K. R., Hudson, B. D., Ulven, T., and Milligan, G. (2014) Treatment of type 2 diabetes by free fatty acid receptor agonists. Front. Endocrinol. 5, 137
45. Kim, M. H., Kang, S. G., Park, J. H., Yanagisawa, M., and Kim, C. H. (2013) Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology 145, 396-406
46. Vinolo, M. A., Rodrigues, H. G., Nachbar, R. T., and Curi, R. (2011) Regulation of inflammation by short chain fatty acids. Nutrients 3, 858-876
47. Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., Pike, N. B., Strum, J. C., Steplewski, K. M., Murdock, P. R., Holder, J. C., et al. (2003) The orphanGprotein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278, 11312-11319
48. Le Poul, E., Loison, C., Struyf, S., Springael, J. Y., Lannoy, V., Decobecq, M. E., Brezillon, S., Dupriez, V., Vassart, G., Van Damme, J., Parmentier, M., and Detheux, M. (2003) Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 278, 25481-254819
49. Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G., Thian, F. S., Kobilka, T. S., Choi, H. J., Kuhn, P., Weis, W. I., Kobilka, B. K., and Stevens, R. C. (2007) High-resolution crystal structure of an engineered human β2-adrenergic G protein-coupled receptor. Science 318, 1258-1265
50. Hoffmann, C., Castro, M., Rinken, A., Leurs, R., Hill S. J., and Vischer, H. F. (2015) Ligand residence time at GPCRs-why we should take our time to study it. Mol. Pharmacol. 88, 552-560
51. McKeage, K. (2015) Tiotropium Respimat®: a review of its use in asthma poorly controlled with inhaled corticosteroids and long-acting β2-adrenergic agonists. Drugs 75, 809-816
52. Pan, A. C., Borhani, D. W., Dror, R. O., and Shaw, D. E. (2013) Molecular determinants of drug-receptor binding kinetics. Drug Discov. Today 18, 667-673
53. Bindels, L. B., Dewulf, E. M., and Delzenne, N. M. (2013) GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol. Sci. 34, 226-232